Articles by Gerald N. Rogan, MD

Gerald N. Rogan, MD

Back Page: Diagnostic Dilemma
November 1, 2004
By: Gerald N. Rogan, MD

Medicare and other payers should consider R&D costs when establishing prices for biotechnology tests-or compromise the industry's future ability to develop targeted therapies.

Most Popular Articles

Off the Hook? Pharm Exec's Annual Press Audit

Does Your Portfolio Review Reflect What the Patient Really Wants?

Only Connect: Finding the Key to Digital Marketing

Innovation: Why is Pharma Scared to Death?

Top Medical Innovations 2012

More Most Popular

Supply Chain Strategy: Managing risk and opportunity in a changing global landscape
Sponsored By PricewaterhouseCoopers LLP Optimizing the Multi-Sponsor REMS Experience (Risk Evaluation & Mitigation Strategies)
Sponsored By PricewaterhouseCoopers LLP Effective Resource Planning: Reducing Clinical Project Risk and Operating Cost
Sponsored By ClearTrial
ARCHIVED WEBCASTS

2009 Sponsors

2012 Pharm Exec 50

Ranks the world's largest pharmaceutical companies by global sales of prescription drugs
sponsored by:

Pharma Country Reports
Market reports on pharma developments worldwide
sponsored by:

SPONSORED LINKS